Загрузка...
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways with...
Сохранить в:
| Опубликовано в: : | Oncogene |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718330/ https://ncbi.nlm.nih.gov/pubmed/33037411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01497-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|